Halozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Halozyme Therapeutics (NASDAQ:HALO) announced its earnings results on Tuesday. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02, Zacks reports. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $57.90 on Wednesday. The stock has a market capitalization of $7.37 billion, a P/E ratio of 19.17, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 1 year low of $35.50 and a 1 year high of $65.53. The firm has a 50 day moving average of $52.69 and a 200-day moving average of $54.51.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.